Table 4 Sensitivity analysis

Base case

31,147

Detection benefit from screening

 4 years

34,927

 6 years

27,005

Screening costs

 +20 %

31,636

 −20 %

30,708

Incremental intensified glycemic treatment costs

 +20 %

33,558

 −20 %

28,759

Incremental intensified hypertension treatment costs

 +20 %

31,083

 −20 %

31,234

Complication costs

 +20 %

30,876

 −20 %

31,442

Discount rates applied to costs and QALYs

 1 %

21,281

 10 %

44,424

Utility weights associated with diabetes

 +20 %

26,874

 −20 %

36,977

Effects of intensive glycemic control

 CHD risk reduction: 20 %

15,688

 Stroke risk reduction: 20 %

28,029

 CHD and stroke risk reduction: 20 %

14,769

Scenario Analysis

 Selective screening of screening of hypertensive individuals only

22,695

 Control group not receiving intensive glucose and hypertension treatment

7505